Transdermal delivery of dehydroepiandrosterone
OwnerJerry Rosenbauminventor
Life of this patent
Estimating the term…
Abstract
Disclosed is a novel transdermal delivery system for dehydroepiandrosterone (DHEA). Using phospholipids as vehicles, DHEA can be administered into and through the skin when topically applied. Numerous advantages apply to this modality of therapy.
Claims34
A transdermal patch for administering dehydroepiandrosterone to a person and increasing the serum concentration of dehydroepiandrosterone in such person, comprising a reservoir and a composition comprising an effective amount in the range of 0.1 grams to 25 grams per 100 grams of composition of at least one dehydroepiandrosterone compound and an effective amount to increase the transdermal transmission thereof in the range of 1 gram to 90 grams per 100 grams of composition of at least one phospholipid skin penetration enhancer therefor.
The method of enhancing the serum concentration of dehydroepiandrosterone in a person, comprising transdermally administering to said person a non-staining topical composition comprising an effective amount of at least one dehydroepiandrosterone compound and an amount effective to increase the transdermal transmission thereof of at least one phospholipid for a period of time sufficient to achieve an above baseline serum concentration of dehydroepiandrosterone.
Dependencies are inferred from the claim text.